Ignite Creation Date:
2024-05-06 @ 1:17 PM
Last Modification Date:
2024-10-26 @ 1:11 PM
Study NCT ID:
NCT03980730
Status:
TERMINATED
Last Update Posted:
2022-01-21
First Post:
2019-05-31
Brief Title:
Study of Azeliragon in Patients With Mild Alzheimers Disease and Impaired Glucose Tolerance
Sponsor:
vTv Therapeutics
Organization:
vTv Therapeutics
Study Overview
Official Title:
Randomized Double-blind Placebo-controlled Multicenter Studies to Evaluate the Safety and Efficacy of Azeliragon as a Treatment for Subjects With Mild Alzheimers Disease and Impaired Glucose Tolerance
Status:
TERMINATED
Status Verified Date:
2021-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
for business reasons
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Elevage
Brief Summary:
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimers disease and impaired glucose tolerance Patients will receive either azeliragon or placebo with a patients participation lasting approximately 9 months in Part 1 or 21 months in Part 2
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None